PSG6

Across TCGA pan-cancer cohorts, PSG6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSG6 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PSG6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSG6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, ACC, and LIHC are the cancer types where PSG6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.055	0.787	<.001	30	view →
ACC	DFS	Median	All	0.195	0.748	.003	9	view →
LIHC	DFS	Median	All	0.029	0.556	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.631	.033	4	view →
LUSC	DFS	Median	III,IV	0.215	0.638	.043	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSG6–COAD (OS)

Open the COAD breakdown →